Cancer Metastasis and Target for Treatment
Keywords:
metastasis, cancer treatment; metastatic cancer; targeted drug; cancerAbstract
Metastasis is a process that cancer cells spread from a primary site to different parts of the body. It is the major cause of cancer death. The metastasis involved multiple sequential steps in which numerous biochemical molecules have been implicated in the process. Insight understanding the role of such molecular components is important for metastasis prevention and inhibition. To produce clinically effective therapeutic outcomes, several compounds targeting metastasis processes have been developed and are currently under study in various phases of clinical testing for treatment of metastatic cancers, in expectation, further reduce cancer mortality rate.
References
1. Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog 2013; 18: 43-73.
2. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B 2015; 5: 402-18.
3. Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med 2010; 31: 205-14.
4. Kirfel G, Rigort A, Borm B, Herzog V. Cell migration: mechanisms of rear detachment and the formation of migration tracks. Eur J Cell Biol 2004; 83: 717-24.
5. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004; 16: 14-23.
6. Hecht I, Bar-El Y, Balmer F, Natan S, Tsarfaty I, Schweitzer F, et al. Tumor invasion optimization by mesenchymal-amoeboid heterogeneity. Sci Rep 2015; 5: 10622.
7. Korthuis RJ, Anderson DC, Granger DN. Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J Crit Care 1994; 9: 47-71.
8. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat 2011; 128: 7-21.
9. Chang HW, Yen CY, Chen CH, Tsai JH, Tang JY, Chang YT, et al. Evaluation of the mRNA expression levels of integrins alpha3, alpha5, beta1 and beta6 as tumor biomarkers of oral squamous cell carcinoma. Oncol Lett 2018; 16: 4773-81.
10. Pal M, Bhattacharya S, Kalyan G, Hazra S. Cadherin profiling for therapeutic interventions in Epithelial Mesenchymal Transition (EMT) and tumorigenesis. Exp Cell Res 2018; 368: 137-46.
11. Luo Y, Yu T, Zhang Q, Fu Q, Hu Y, Xiang M, et al. Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis. Eur J Clin Invest 2018; 48: doi: 10.1111/eci.12903.
12. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010; 20: 169-77.
13. Qi C, Li B, Guo S, Wei B, Shao C, Li J, et al. P-Selectin-Mediated Adhesion between Platelets and Tumor Cells Promotes Intestinal Tumorigenesis in Apc(Min/+) Mice. Int J Biol Sci 2015; 11: 679-87.
14. Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, et al. Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS One 2013; 8: e85143.
15. Perfilyeva YV, Abdolla N, Ostapchuk YO, Tleulieva R, Krasnoshtanov VC, Perfilyeva AV, et al. Chronic Inflammation Contributes to Tumor Growth: Possible Role of L-Selectin-Expressing Myeloid-Derived Suppressor Cells (MDSCs). Inflammation 2018. doi: 10.1007/s10753-018-0892-6.
16. Rapanotti MC, Suarez Viguria TM, Costanza G, Ricozzi I, Pierantozzi A, Di Stefani A, et al. Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma. Arch Dermatol Res 2014; 306: 527-37.
17. Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, et al. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Mol Cancer Ther 2015; 14: 821-7.
18. Wang J, Tang X, Weng W, Qiao Y, Lin J, Liu W, et al. The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. Oncogene 2015; 34: 5781-95.
19. Wai Wong C, Dye DE, Coombe DR. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol 2012; 2012: 340296.
20. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008 ; 68: 3323-33.
21. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010; 36: 492-500.
22. Chan SH, Wang LH. Regulation of cancer metastasis by microRNAs. J Biomed Sci 2015; 22: 9.
23. Blaschuk OW. N-cadherin antagonists as oncology therapeutics. Philos Trans R Soc Lond B Biol Sci 2015; 370: 20140039.
24. Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008; 68: 3777-84.
25. Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, et al. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 2009; 20: 741-5.
26. Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollingsworth MA, Wheelock MJ, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer 2008; 122: 71-7.
27. Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumour Biol 2014; 35: 8483-523.
28. Russo MA, Paolillo M, Sanchez-Hernandez Y, Curti D, Ciusani E, Serra M, et al. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int J oncol 2013; 42: 83-92.
29. Paolillo M, Russo MA, Serra M, Colombo L, Schinelli S. Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem 2009; 9: 1439-46.
30. Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther 2018; 17: 1147-55.
31. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012; 2012: 676731.
32. Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep 2014; 8: 1558-70.
33. Hammond E, Khurana A, Shridhar V, Dredge K. The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. Front Oncol 2014; 4: 195.
2. Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B 2015; 5: 402-18.
3. Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med 2010; 31: 205-14.
4. Kirfel G, Rigort A, Borm B, Herzog V. Cell migration: mechanisms of rear detachment and the formation of migration tracks. Eur J Cell Biol 2004; 83: 717-24.
5. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004; 16: 14-23.
6. Hecht I, Bar-El Y, Balmer F, Natan S, Tsarfaty I, Schweitzer F, et al. Tumor invasion optimization by mesenchymal-amoeboid heterogeneity. Sci Rep 2015; 5: 10622.
7. Korthuis RJ, Anderson DC, Granger DN. Role of neutrophil-endothelial cell adhesion in inflammatory disorders. J Crit Care 1994; 9: 47-71.
8. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat 2011; 128: 7-21.
9. Chang HW, Yen CY, Chen CH, Tsai JH, Tang JY, Chang YT, et al. Evaluation of the mRNA expression levels of integrins alpha3, alpha5, beta1 and beta6 as tumor biomarkers of oral squamous cell carcinoma. Oncol Lett 2018; 16: 4773-81.
10. Pal M, Bhattacharya S, Kalyan G, Hazra S. Cadherin profiling for therapeutic interventions in Epithelial Mesenchymal Transition (EMT) and tumorigenesis. Exp Cell Res 2018; 368: 137-46.
11. Luo Y, Yu T, Zhang Q, Fu Q, Hu Y, Xiang M, et al. Upregulated N-cadherin expression is associated with poor prognosis in epithelial-derived solid tumours: A meta-analysis. Eur J Clin Invest 2018; 48: doi: 10.1111/eci.12903.
12. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010; 20: 169-77.
13. Qi C, Li B, Guo S, Wei B, Shao C, Li J, et al. P-Selectin-Mediated Adhesion between Platelets and Tumor Cells Promotes Intestinal Tumorigenesis in Apc(Min/+) Mice. Int J Biol Sci 2015; 11: 679-87.
14. Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, et al. Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS One 2013; 8: e85143.
15. Perfilyeva YV, Abdolla N, Ostapchuk YO, Tleulieva R, Krasnoshtanov VC, Perfilyeva AV, et al. Chronic Inflammation Contributes to Tumor Growth: Possible Role of L-Selectin-Expressing Myeloid-Derived Suppressor Cells (MDSCs). Inflammation 2018. doi: 10.1007/s10753-018-0892-6.
16. Rapanotti MC, Suarez Viguria TM, Costanza G, Ricozzi I, Pierantozzi A, Di Stefani A, et al. Sequential molecular analysis of circulating MCAM/MUC18 expression: a promising disease biomarker related to clinical outcome in melanoma. Arch Dermatol Res 2014; 306: 527-37.
17. Onstenk W, Kraan J, Mostert B, Timmermans MM, Charehbili A, Smit VT, et al. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Mol Cancer Ther 2015; 14: 821-7.
18. Wang J, Tang X, Weng W, Qiao Y, Lin J, Liu W, et al. The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. Oncogene 2015; 34: 5781-95.
19. Wai Wong C, Dye DE, Coombe DR. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol 2012; 2012: 340296.
20. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008 ; 68: 3323-33.
21. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 2010; 36: 492-500.
22. Chan SH, Wang LH. Regulation of cancer metastasis by microRNAs. J Biomed Sci 2015; 22: 9.
23. Blaschuk OW. N-cadherin antagonists as oncology therapeutics. Philos Trans R Soc Lond B Biol Sci 2015; 370: 20140039.
24. Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008; 68: 3777-84.
25. Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, et al. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 2009; 20: 741-5.
26. Shintani Y, Fukumoto Y, Chaika N, Grandgenett PM, Hollingsworth MA, Wheelock MJ, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer 2008; 122: 71-7.
27. Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. Tumour Biol 2014; 35: 8483-523.
28. Russo MA, Paolillo M, Sanchez-Hernandez Y, Curti D, Ciusani E, Serra M, et al. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int J oncol 2013; 42: 83-92.
29. Paolillo M, Russo MA, Serra M, Colombo L, Schinelli S. Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem 2009; 9: 1439-46.
30. Winer A, Adams S, Mignatti P. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes. Mol Cancer Ther 2018; 17: 1147-55.
31. Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol 2012; 2012: 676731.
32. Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep 2014; 8: 1558-70.
33. Hammond E, Khurana A, Shridhar V, Dredge K. The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics. Front Oncol 2014; 4: 195.
Downloads
Published
2019-04-01
How to Cite
1.
Kaewmeesri P, Senggunprai L. Cancer Metastasis and Target for Treatment. SRIMEDJ [Internet]. 2019 Apr. 1 [cited 2024 Nov. 25];34(2):211-6. Available from: https://li01.tci-thaijo.org/index.php/SRIMEDJ/article/view/181377
Issue
Section
Review Articles
